



 **ATS**  
2023

**Washington, DC**  
May 19-24



## **Industry Press Release**

**Date:** May 1, 2023

**Company:** Zambon

**Media Contact:** Elixir Health Public Relations. Lindsay Rocco

**Contact email and phone number:**

+1 862-596-1304 and [lrocco@elixirhealthpr.com](mailto:lrocco@elixirhealthpr.com)

**Title of Press Release:** Zambon Completes Enrollment in Phase 3 Clinical Development Program Evaluating Liposomal Cyclosporine A for Inhalation (L-CsA-i) in Patients with Bronchiolitis Obliterans Syndrome (BOS)

**Link to Press Release:**

<https://www.prnewswire.com/news-releases/zambon-completes-enrollment-in-phase-3-clinical-development-program-evaluating-liposomal-cyclosporine-a-for-inhalation-l-csa-i-in-patients-with-bronchiolitis-obliterans-syndrome-bos-301810878.html?tc>

**Lead Paragraph:**

MILAN and BOSTON, May 1, 2023 /PRNewswire/ -- Zambon, a multinational pharmaceutical company focused on innovating cure and care to improve people's health and the quality of patients' lives, announced today that the Company has completed enrollment in its two pivotal Phase 3 studies. The trials are designed to evaluate the safety and efficacy of Liposomal Cyclosporine A for Inhalation (L-CsA-i) for the treatment of BOS in adults following single lung ([BOSTON-1](#)) or double lung ([BOSTON-2](#)) transplantation.

